Cullinan Therapeutics, Inc. Operating Income Loss

Quick Answer

Cullinan Therapeutics, Inc. reported Operating Income Loss of -$241.65 million for the year ending 2025.

  • Cullinan Therapeutics, Inc. showed a decrease of -22.7% in Operating Income Loss from 2024 to 2025.
  • This data is from Cullinan Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2020 to 2025), Cullinan Therapeutics, Inc.'s Operating Income Loss has declined by 300.5%.
  • Historical annual values: Fiscal year 2025: -$241.65 million | Fiscal year 2024: -$196.92 million | Fiscal year 2023: -$191.09 million | Fiscal year 2022: $144.65 million | Fiscal year 2021: -$67.95 million | Fiscal year 2020: -$60.34 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: